The oral drug – Johnson & Johnson's Balversa (erdafitinib ... approved in the EU and other markets including the US. Bladder cancer saw few therapeutic advances for decades until the ...

The SunRISe-2 study, in people with muscle-invasive bladder cancer (MIBC ... formulation of J&J's FGFR kinase inhibitor Balversa (erdafitinib), which started the phase 3 MoonRISe-1 trial in ...

ABC UK and bladder cancer patients welcome the approval of Erdafitinib for use in England. There are very few treatments available for bladder cancer in general, and particularly for people with ...

Cancer treatments can instigate ocular surface disease and other deleterious ocular side effects that optometrists can oversee and manage.

Bavencio improved survival in patients with bladder cancer, irrespective of diabetes status, according to an analysis of the ...

Antibody-drug conjugates combined with immunotherapy have redefined the standard of care for advanced bladder cancer, ...

A supplemental biologics license application has been submitted to the FDA for nogapendekin alfa plus Bacillus ...

During a live event, Matthew Galsky, MD, discussed adjuvant nivolumab in muscle-invasive bladder cancer and the benefit in ...

It separates the bladder from other body organs, such as the prostate and kidneys. Doctors describe your bladder cancer based on how far it has spread through these layers. You can have: non muscle ...